WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price...
WESTFIELD, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today...
Zura Bio Limited (“Zura”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the closing of its business...
JATT Acquisition Corp (NYSE: JATT) (“JATT”), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed business combination with Zura...
JATT Acquisition Corp (NYSE: JATT, JATT.WS and JATT.U) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its Class...
JATT Acquisition Corp (NYSE: “JATT”), the publicly traded special purpose acquisition company (“SPAC”), has today announced that the U.S. Securities and Exchange Commission (“SEC”) has declared...
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Zura Bio Limited (“Zura Bio”), a clinical-stage biotechnology company focused on developing novel medicines for immune disorders, and JATT Acquisition Corp. (“JATT”) (NYSE: JATT, JATT.U, JATT.WS),...